Head, Paediatric & Population-Based Dermatology Research, St John's Institute of Dermatology
Carsten Flohr studied at Cambridge and Oxford Universities and then trained in both paediatrics and dermatology. He was the first UK National Institute for Health Research (NIHR) Clinician Scientist in Dermatology (2009-2014) and also held a Career Development Fellowship from the NIHR (2014-2020).
Carsten Flohr is Chair in Dermatology and Population Health Sciences at King’s College London and Honorary Consultant in Dermatology as well as Research & Development Lead at St John’s Institute of Dermatology, Guy’s & St Thomas’ NHS Foundation Trust, London, UK.
Professor Flohr has a particular interest in population-based dermatology research and clinical trials with a focus on atopic eczema. For instance, he is Chief Investigator of the NIHR-funded TREatment of severe eczema in children Trial (TREAT), which compares ciclosporine with methotrexate in children with recalcitrant atopic eczema. He is also Chief Investigator of the UK-Irish Atopic Eczema Systemic Therapy Register (A-STAR) and the EU Horizon 2020 Joint Program Initiative-funded Trans-Foods and the Mind & Skin consortia. The Flohr Group also investigates host-skin and gut microbiome interactions in inflammatory skin disease. In addition, Professor Flohr leads the International League of Dermatological Societies (ILDS) Global Atopic Dermatitis Atlas project.
Professor Flohr is a Founding Director of the International Eczema Council and Past President of the British Society of Paediatric and Adolescent Dermatology. He is also Founding Editor of the Evidence-Based Dermatology Section of the British Journal of Dermatology and the Clinical Trials Editor of the F1000 Atopic Dermatitis Section.
The Paediatric & Population-Based Dermatology Research is based at St Thomas’ Hospital and is led by Professor Carsten Flohr.
The SOFTER Trial is a controlled study that looks at an ion-exchange water softener for the prevention of atopic eczema in newborn babies.
Project status: Completed
Funding from the LEO Foundation marks a significant milestone for GADA
Findings from a clinical trial has recommended methotrexate for children with severe atopic dermatitis.
Atopic dermatitis, or eczema, affects around 20% of children and 10% of adults and can have a profound impact on patients’ quality of life. A chronic...
Analysis of data from a trial of more than 1,300 infants has found that increased application of moisturisers at three months of age was associated with a...
A new study to understand the interaction of gut bacteria, diet and disease has linked gut bacteria with eczema and caesarean section birth.
A wide-ranging study has compared systemic treatments for eczema for the first time.
Researchers have found that the use of moisturisers on newborn babies does not prevent eczema, as previously thought.
The Paediatric & Population-Based Dermatology Research is based at St Thomas’ Hospital and is led by Professor Carsten Flohr.
The SOFTER Trial is a controlled study that looks at an ion-exchange water softener for the prevention of atopic eczema in newborn babies.
Project status: Completed
Funding from the LEO Foundation marks a significant milestone for GADA
Findings from a clinical trial has recommended methotrexate for children with severe atopic dermatitis.
Atopic dermatitis, or eczema, affects around 20% of children and 10% of adults and can have a profound impact on patients’ quality of life. A chronic...
Analysis of data from a trial of more than 1,300 infants has found that increased application of moisturisers at three months of age was associated with a...
A new study to understand the interaction of gut bacteria, diet and disease has linked gut bacteria with eczema and caesarean section birth.
A wide-ranging study has compared systemic treatments for eczema for the first time.
Researchers have found that the use of moisturisers on newborn babies does not prevent eczema, as previously thought.
